{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:17:24Z","timestamp":1791404244886,"version":"4.3.3"},"reference-count":128,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":128,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cystic fibrosis (CF) lung disease imposes a significant clinical, psychosocial, and economic burden on people with CF (pwCF), their caregivers, and healthcare systems. Although the introduction of CF transmembrane conductance regulator (CFTR) modulator therapies has led to significant improvements in symptoms, lung function, exacerbations, and quality of life, substantial burden remains. A subset of pwCF taking CFTR modulator therapy experience residual infection, neutrophilic inflammation (to levels seen in non-CF bronchiectasis), exacerbations, and pulmonary complications. Furthermore, 10%-15% of the global CF population is either ineligible for or intolerant to current CFTR modulator therapies, with some pwCF (although in the minority) experiencing adverse events that necessitate treatment discontinuation. For these people, the burden of disease remains. The worsening of mental health experienced by some pwCF on CFTR modulator therapy adds to the psychosocial burden. Although some evidence suggests a decrease in treatment burden, in general, CFTR modulators have been added to therapeutic regimens rather than replacing symptomatic treatments. While reductions in healthcare resource use have been reported, hospitalizations and emergency department visits, and their associated costs, have not been eliminated. Given the expected improvements in life expectancy following the introduction of these therapies, the burden is likely to continue into old age. A better understanding of the residual clinical, psychosocial, and economic burden that lung disease imposes on pwCF in the era of CFTR modulator therapy highlights the remaining unmet needs and could assist healthcare systems in better planning resource allocation.<\/jats:p>","DOI":"10.1513\/annalsats.202408-800fr","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T17:46:29Z","timestamp":1758131189000},"page":"17-29","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":6,"title":["The clinical, psychosocial, and economic burden of cystic fibrosis lung disease in the era of CFTR modulator therapy"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-1486","authenticated-orcid":false,"given":"Isabelle","family":"Fajac","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Facult\u00e9 de Sant\u00e9 , Paris,","place":["France"]},{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris, H\u00f4pital Cochin, Service de Physiologie et Explorations Fonctionnelles , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-7374","authenticated-orcid":false,"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-2199","authenticated-orcid":false,"given":"Marcus A","family":"Mall","sequence":"additional","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin , Berlin,","place":["Germany"]},{"name":"German Center for Lung Research (DZL), associated partner site Berlin , Berlin,","place":["Germany"]},{"name":"German Center for Child and Adolescent Health (DZKJ), partner site Berlin , Berlin,","place":["Germany"]},{"name":"Cluster of Excellence ImmunoPreCept, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce K","family":"Rubin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Virginia Commonwealth University School of Medicine , Richmond, VA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A","family":"Flume","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Pediatrics, Medical University of South Carolina , Charleston, SC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"2026032210420087200_aaoaf009-B1","doi-asserted-by":"publisher","first-page":"104169","DOI":"10.1016\/j.lpm.2023.104169","article-title":"Cystic fibrosis","volume":"52","author":"Fajac","year":"2023","journal-title":"Presse Med"},{"key":"2026032210420087200_aaoaf009-B2","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"2026032210420087200_aaoaf009-B3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026032210420087200_aaoaf009-B4","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/s0140-6736(23)01608-2","article-title":"The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches","volume":"402","author":"Graeber","year":"2023","journal-title":"Lancet"},{"key":"2026032210420087200_aaoaf009-B5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1183\/20734735.007516","article-title":"Global impact of bronchiectasis and cystic fibrosis","volume":"12","author":"Redondo","year":"2016","journal-title":"Breathe (Sheff)"},{"key":"2026032210420087200_aaoaf009-B6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","article-title":"Cystic fibrosis modulator therapies","volume":"74","author":"Jia","year":"2023","journal-title":"Annu Rev Med"},{"key":"2026032210420087200_aaoaf009-B7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrd3723","article-title":"Ivacaftor","volume":"11","author":"Davis","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"2026032210420087200_aaoaf009-B8","author":"Cystic Fibrosis Foundation"},{"key":"2026032210420087200_aaoaf009-B9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/s2213-2600(24)00407-7","article-title":"Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE trial VX21-121-105): an analysis from a single-arm, phase 3 trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026032210420087200_aaoaf009-B10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/s2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026032210420087200_aaoaf009-B11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/d41573-025-00008-y","article-title":"FDA approves next-generation triple therapy for cystic fibrosis","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"2026032210420087200_aaoaf009-B12","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"2026032210420087200_aaoaf009-B13","doi-asserted-by":"publisher","first-page":"00082","DOI":"10.1183\/23120541.00082-2019","article-title":"Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles","volume":"5","author":"Taylor-Cousar","year":"2019","journal-title":"ERJ Open Res"},{"key":"2026032210420087200_aaoaf009-B14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026032210420087200_aaoaf009-B16","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B17","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.3390\/life13061305","article-title":"Future comorbidities in an aging cystic fibrosis population","volume":"13","author":"Ticona","year":"2023","journal-title":"Life (Basel)"},{"key":"2026032210420087200_aaoaf009-B18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jcf.2023.11.008","article-title":"A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI","volume":"23","author":"Gill","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jcf.2020.02.015","article-title":"Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease","volume":"19","author":"Kapnadak","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B20","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jcf.2021.05.009","article-title":"Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease","volume":"20","author":"Bermingham","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B22","doi-asserted-by":"publisher","first-page":"100829","DOI":"10.1016\/j.resmer.2021.100829","article-title":"Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease","volume":"80","author":"Martin","year":"2021","journal-title":"Respir Med Res"},{"key":"2026032210420087200_aaoaf009-B23","doi-asserted-by":"publisher","first-page":"200016","DOI":"10.1183\/20734735.0016-2020","article-title":"The era of CFTR modulators: improvements made and remaining challenges","volume":"16","author":"Cuevas-Oca\u00f1a","year":"2020","journal-title":"Breathe (Sheff)"},{"key":"2026032210420087200_aaoaf009-B24","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1093\/infdis\/jiae051","article-title":"Impact of CFTR modulation on pseudomonas aeruginosa infection in people with cystic fibrosis","volume":"230","author":"Ledger","year":"2024","journal-title":"J Infect Dis"},{"key":"2026032210420087200_aaoaf009-B25","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/thoraxjnl-2020-215556","article-title":"Longitudinal effects of ivacaftor and medicine possession ratio in people with the Gly551Asp mutation: a 5-year study","volume":"76","author":"Mitchell","year":"2021","journal-title":"Thorax"},{"key":"2026032210420087200_aaoaf009-B26","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1164\/rccm.202411-2231OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in adults and adolescents with cystic fibrosis and at least one F508del allele: a phase 3, open-label extension study","volume":"211","author":"Daines","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B27","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.jcf.2025.04.012","article-title":"LONGITUDE: an observational study of the long-term effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people aged \u226512 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry\u20142-year analysis","volume":"24","author":"Vega-Hernandez","year":"2025","journal-title":"J Cyst Fibrosis"},{"key":"2026032210420087200_aaoaf009-B28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1569-1993(24)00963-9","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on long-term lung function and BMI trajectory","volume":"23","author":"Solomon","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B29","author":"US Food and Drug Administration"},{"key":"2026032210420087200_aaoaf009-B30","doi-asserted-by":"publisher","first-page":"220154","DOI":"10.1183\/16000617.0154-2022","article-title":"Role of inhaled antibiotics in the era of highly effective CFTR modulators","volume":"32","author":"Elborn","year":"2023","journal-title":"Eur Respir Rev"},{"key":"2026032210420087200_aaoaf009-B31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr Pulmonol"},{"key":"2026032210420087200_aaoaf009-B32","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ppul.20619","article-title":"Predictors of mortality in adults with cystic fibrosis","volume":"42","author":"Courtney","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"2026032210420087200_aaoaf009-B33","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jpeds.2007.03.006","article-title":"Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis","volume":"151","author":"Konstan","year":"2007","journal-title":"J Pediatr"},{"key":"2026032210420087200_aaoaf009-B34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ppul.2009","article-title":"Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition","volume":"32","author":"Kosorok","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"2026032210420087200_aaoaf009-B35","author":"Cystic Fibrosis Foundation","year":"2023"},{"key":"2026032210420087200_aaoaf009-B36","author":"Zolin"},{"key":"2026032210420087200_aaoaf009-B37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1569-1993(24)01552-2","article-title":"Association between change in Pseudomonas aeruginosa infection and clinical outcomes after elexacaftor\/tezacaftor\/ivacaftor treatment: data from the European Cystic Fibrosis Society Patient Registry","volume":"23","author":"Pollak","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B38","doi-asserted-by":"publisher","first-page":"e167957","DOI":"10.1172\/JCI16795","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"2026032210420087200_aaoaf009-B39","doi-asserted-by":"publisher","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"key":"2026032210420087200_aaoaf009-B40","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/thorax-2022-219943","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis","volume":"78","author":"Casey","year":"2023","journal-title":"Thorax"},{"key":"2026032210420087200_aaoaf009-B41","doi-asserted-by":"publisher","first-page":"00724","DOI":"10.1183\/23120541.00724-2021","article-title":"CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011-2018","volume":"8","author":"Ricotta","year":"2022","journal-title":"ERJ Open Res"},{"key":"2026032210420087200_aaoaf009-B42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jcf.2023.05.003","article-title":"Eradication of nontuberculous mycobacteria in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor: a multicenter cohort study","volume":"23","author":"Wiesel","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B43","doi-asserted-by":"publisher","first-page":"240068","DOI":"10.1183\/16000617.0068-2024","article-title":"Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy","volume":"33","author":"Milczewska","year":"2024","journal-title":"Eur Respir Rev"},{"key":"2026032210420087200_aaoaf009-B44","doi-asserted-by":"publisher","first-page":"11865","DOI":"10.3390\/ijms252211865","article-title":"Highly effective modulator therapy: implications for the microbial landscape in cystic fibrosis","volume":"25","author":"Valladares","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026032210420087200_aaoaf009-B45","doi-asserted-by":"publisher","first-page":"21700","DOI":"10.1038\/s41598-020-78817-x","article-title":"(R)-roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages","volume":"10","author":"Shrestha","year":"2020","journal-title":"Sci Rep"},{"key":"2026032210420087200_aaoaf009-B46","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1513\/AnnalsATS.201902-122OC","article-title":"Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens. A cohort study using national registry data","volume":"16","author":"Frost","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2026032210420087200_aaoaf009-B47","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B48","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/thx.2006.060889","article-title":"Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis","volume":"62","author":"Goss","year":"2007","journal-title":"Thorax"},{"key":"2026032210420087200_aaoaf009-B49","doi-asserted-by":"publisher","first-page":"e0240452","DOI":"10.1371\/journal.pone.0240452","article-title":"Clinical impact of respiratory virus in pulmonary exacerbations of children with cystic fibrosis","volume":"15","author":"Meyer","year":"2020","journal-title":"PLoS One"},{"key":"2026032210420087200_aaoaf009-B50","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/thoraxjnl-2014-206750","article-title":"Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis","volume":"71","author":"Heltshe","year":"2016","journal-title":"Thorax"},{"key":"2026032210420087200_aaoaf009-B51","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1378\/chest.121.1.64","article-title":"Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis","volume":"121","author":"Britto","year":"2002","journal-title":"Chest"},{"key":"2026032210420087200_aaoaf009-B52","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ppul.21374","article-title":"Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis","volume":"46","author":"Sanders","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"2026032210420087200_aaoaf009-B53","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/ppul.21117","article-title":"Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis","volume":"45","author":"Sanders","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"2026032210420087200_aaoaf009-B54","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1164\/rccm.200202-087OC","article-title":"Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality","volume":"166","author":"Mayer-Hamblett","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B55","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/aje\/153.4.345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"Am J Epidemiol"},{"key":"2026032210420087200_aaoaf009-B56","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"2026032210420087200_aaoaf009-B57","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s41030-021-00158-5","article-title":"Real-world long-term ivacaftor for cystic fibrosis in France: clinical effectiveness and healthcare resource utilization","volume":"7","author":"Hubert","year":"2021","journal-title":"Pulm Ther"},{"key":"2026032210420087200_aaoaf009-B58","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jcf.2018.07.011","article-title":"Lumacaftor\/ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV(1)","volume":"18","author":"McColley","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026032210420087200_aaoaf009-B60","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of lumacaftor-ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B61","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026032210420087200_aaoaf009-B62","doi-asserted-by":"publisher","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026032210420087200_aaoaf009-B63","doi-asserted-by":"publisher","first-page":"106073","DOI":"10.1016\/j.rmed.2020.106073","article-title":"Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function","volume":"171","author":"Salvatore","year":"2020","journal-title":"Respir Med"},{"key":"2026032210420087200_aaoaf009-B64","doi-asserted-by":"publisher","first-page":"00203","DOI":"10.1183\/23120541.00203-2020","article-title":"Lumacaftor\/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis","volume":"7","author":"King","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026032210420087200_aaoaf009-B65","doi-asserted-by":"publisher","first-page":"106646","DOI":"10.1016\/j.rmed.2021.106646","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del\/minimal function genotype","volume":"189","author":"Carnovale","year":"2021","journal-title":"Respir Med"},{"key":"2026032210420087200_aaoaf009-B66","doi-asserted-by":"publisher","first-page":"e01015","DOI":"10.1002\/prp2.1015","article-title":"Real-life efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor on severe cystic fibrosis lung disease patients","volume":"10","author":"Kos","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"2026032210420087200_aaoaf009-B67","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jcf.2024.04.004","article-title":"Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations","volume":"23","author":"Cogen","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B68","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jcf.2017.06.002","article-title":"Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor","volume":"17","author":"Flume","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B69","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1055\/s-0039-1697639","article-title":"Pulmonary complications of cystic fibrosis","volume":"40","author":"Garcia","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B70","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1378\/chest.128.2.720","article-title":"Pneumothorax in cystic fibrosis","volume":"128","author":"Flume","year":"2005","journal-title":"Chest"},{"key":"2026032210420087200_aaoaf009-B71","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.prrv.2012.01.003","article-title":"Cystic fibrosis: management of haemoptysis","volume":"13","author":"Hurt","year":"2012","journal-title":"Paediatr Respir Rev"},{"key":"2026032210420087200_aaoaf009-B72","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1148\/rg.2018170122","article-title":"An interventionalist\u2019s guide to hemoptysis in cystic fibrosis","volume":"38","author":"Monroe","year":"2018","journal-title":"Radiographics"},{"key":"2026032210420087200_aaoaf009-B73","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1378\/chest.128.2.729","article-title":"Massive hemoptysis in cystic fibrosis","volume":"128","author":"Flume","year":"2005","journal-title":"Chest"},{"key":"2026032210420087200_aaoaf009-B74","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1513\/AnnalsATS.202202-110OC","article-title":"Hemoptysis and the risk for lung transplant or death without transplant in individuals with cystic fibrosis in the United States","volume":"19","author":"Bayomy","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026032210420087200_aaoaf009-B75","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"key":"2026032210420087200_aaoaf009-B76","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles","volume":"206","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B77","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older\u2014the RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B78","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1165\/rcmb.2021-0359OC","article-title":"Cystic fibrosis airway mucus hyperconcentration produces a vicious cycle of mucin, pathogen, and inflammatory interactions that promotes disease persistence","volume":"67","author":"Batson","year":"2022","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026032210420087200_aaoaf009-B79","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jcf.2022.03.011","article-title":"Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis","volume":"21","author":"Wucherpfennig","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B80","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1513\/AnnalsATS.202208-684OC","article-title":"Effects of lumacaftor\/ivacaftor on cystic fibrosis disease progression in children 2 through 5 years of age homozygous for F508del-CFTR: a phase 2 placebo-controlled clinical trial","volume":"20","author":"Stahl","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"2026032210420087200_aaoaf009-B81","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/thoraxjnl-2017-210473","article-title":"The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers","volume":"73","author":"Rowbotham","year":"2018","journal-title":"Thorax"},{"key":"2026032210420087200_aaoaf009-B82","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026032210420087200_aaoaf009-B83","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1513\/AnnalsATS.202404-366OC","article-title":"Impact of discontinuing both hypertonic saline and dornase alfa after elexacaftor-tezacaftor-ivacaftor in cystic fibrosis","volume":"21","author":"Mayer-Hamblett","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026032210420087200_aaoaf009-B84","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1513\/AnnalsATS.202308-735RL","article-title":"Assessing safety of discontinuing hypertonic saline in those with lower forced expiratory volume in 1 second after elexacaftor\/tezacaftor\/ivacaftor","volume":"21","author":"Nichols","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026032210420087200_aaoaf009-B85","author":"NHS Health Research Authority"},{"key":"2026032210420087200_aaoaf009-B86","doi-asserted-by":"publisher","first-page":"100080","DOI":"10.1016\/j.chpulm.2024.100080","article-title":"Using real-world research to study the impact of chronic daily therapy discontinuation in cystic fibrosis: the Home-Reported Outcomes in Cystic Fibrosis 2 study design","volume":"2","author":"Rosen","year":"2024","journal-title":"CHEST Pulmon"},{"key":"2026032210420087200_aaoaf009-B87","doi-asserted-by":"publisher","first-page":"e153-e162","DOI":"10.1016\/j.crad.2013.10.023","article-title":"Pulmonary complications of cystic fibrosis","volume":"69","author":"Ng","year":"2014","journal-title":"Clin Radiol"},{"key":"2026032210420087200_aaoaf009-B88","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026032210420087200_aaoaf009-B89","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.jcf.2019.11.007","article-title":"Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy","volume":"19","author":"Gifford","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B90","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcf.2024.08.008","article-title":"Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the SIMPLIFY randomized, controlled trial","volume":"24","author":"Gifford","year":"2025","journal-title":"J Cyst Fibrosis"},{"key":"2026032210420087200_aaoaf009-B91","doi-asserted-by":"publisher","first-page":"20406223241264477","DOI":"10.1177\/20406223241264477","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on cystic fibrosis health-related quality of life and decision-making about daily treatment regimens: a mixed methods exploratory study","volume":"15","author":"Basile","year":"2024","journal-title":"Ther Adv Chronic Dis"},{"key":"2026032210420087200_aaoaf009-B92","doi-asserted-by":"publisher","first-page":"190112","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"Shteinberg","year":"2020","journal-title":"Eur Respir Rev"},{"key":"2026032210420087200_aaoaf009-B93","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Dagenais","year":"2020","journal-title":"J Clin Med"},{"key":"2026032210420087200_aaoaf009-B94","doi-asserted-by":"publisher","first-page":"1531514","DOI":"10.3389\/fphar.2025.1531514","article-title":"Real-world safety profile of elexacaftor\/tezacaftor\/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system","volume":"16","author":"Zhu","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026032210420087200_aaoaf009-B95","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1002\/ppul.24937","article-title":"Enhancing care for individuals with advanced cystic fibrosis lung disease","volume":"56(Suppl 1)","author":"Kapnadak","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2026032210420087200_aaoaf009-B96","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.psym.2017.04.001","article-title":"Cystic fibrosis transmembrane regulator modulators: implications for the management of depression and anxiety in cystic fibrosis","volume":"58","author":"Talwalkar","year":"2017","journal-title":"Psychosomatics"},{"key":"2026032210420087200_aaoaf009-B97","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00127-022-02307-w","article-title":"Depression and anxiety prevalence in people with cystic fibrosis and their caregivers: a systematic review and meta-analysis","volume":"58","author":"Lord","year":"2023","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"2026032210420087200_aaoaf009-B98","doi-asserted-by":"publisher","first-page":"1179208","DOI":"10.3389\/fphar.2023.1179208","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on mental health of patients with cystic fibrosis","volume":"14","author":"Piehler","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026032210420087200_aaoaf009-B99","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment and depression-related events","volume":"209","author":"Ramsey","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B100","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1164\/rccm.202311-2159ED","article-title":"Questions and answers? Depression symptoms associated with elexacaftor\/tezacaftor\/ivacaftor treatment for cystic fibrosis","volume":"209","author":"Lee","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B101","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jcf.2017.05.008","article-title":"Worsening anxiety and depression after initiation of lumacaftor\/ivacaftor combination therapy in adolescent females with cystic fibrosis","volume":"16","author":"McKinzie","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B102","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/mcp.0000000000001014","article-title":"Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort","volume":"29","author":"VanElzakker","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"2026032210420087200_aaoaf009-B103","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12913-015-1061-3","article-title":"Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom","volume":"15","author":"Angelis","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"2026032210420087200_aaoaf009-B104","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jcf.2022.06.003","article-title":"Elexacaftor-tezacaftor-ivacaftor improve gastro-oesophageal reflux and sinonasal symptoms in advanced cystic fibrosis","volume":"21","author":"Shakir","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B105","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/jcm11041021","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation and advanced lung disease: a 48-week observational study","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"2026032210420087200_aaoaf009-B106","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/ppul.26318","article-title":"Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis","volume":"58","author":"McCoy","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026032210420087200_aaoaf009-B107","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.arbres.2023.05.017","article-title":"Experience with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced disease","volume":"59","author":"Carrasco Hernandez","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"2026032210420087200_aaoaf009-B108","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jcf.2018.12.004","article-title":"Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis","volume":"18","author":"Flume","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B109","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jcf.2021.08.011","article-title":"The impact of cystic fibrosis on the working life of patients: a systematic review","volume":"21","author":"Leso","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B110","doi-asserted-by":"publisher","first-page":"17534666221086416","DOI":"10.1177\/17534666221086416","article-title":"Caregiver burden in cystic fibrosis: a systematic literature review","volume":"16","author":"Daly","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"2026032210420087200_aaoaf009-B111","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/13696998.2024.2373000","article-title":"Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor\/ivacaftor: an assessment using linked registry data in Sweden","volume":"27","author":"Lindblad","year":"2024","journal-title":"J Med Econ"},{"key":"2026032210420087200_aaoaf009-B112","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jcf.2024.06.010","article-title":"Wellness in the modulator era: an observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis","volume":"24","author":"Van Citters","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B113","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.chest.2018.07.025","article-title":"Critical care of the adult patient with cystic fibrosis","volume":"155","author":"King","year":"2019","journal-title":"Chest"},{"key":"2026032210420087200_aaoaf009-B114","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/ejhpharm-2020-002676","article-title":"Tezacaftor-ivacaftor use in routine care of adults with cystic fibrosis: a medicine use evaluation","volume":"30","author":"Paterson","year":"2023","journal-title":"Eur J Hosp Pharm"},{"key":"2026032210420087200_aaoaf009-B115","doi-asserted-by":"publisher","first-page":"599","DOI":"10.18553\/jmcp.2023.29.6.599","article-title":"Real-world outcomes and direct care cost before and after elexacaftor\/tezacaftor\/ivacaftor initiation in commercially insured members with cystic fibrosis","volume":"29","author":"Marshall","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"2026032210420087200_aaoaf009-B116","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/MCP.0000000000000819","article-title":"Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world\u2014opportunities and challenges","volume":"27","author":"Barry","year":"2021","journal-title":"Curr Opin Pulm Med"},{"key":"2026032210420087200_aaoaf009-B117","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B118","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B119","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1164\/rccm.202310-1836OC","article-title":"Pharmacological improvement of cystic fibrosis transmembrane conductance regulator function rescues airway epithelial homeostasis and host defense in children with cystic fibrosis","volume":"209","author":"Loske","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032210420087200_aaoaf009-B120","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1053\/j.gastro.2004.07.006","article-title":"CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis","volume":"127","author":"Hirtz","year":"2004","journal-title":"Gastroenterology"},{"key":"2026032210420087200_aaoaf009-B121","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/s2213-2600(22)00504-5","article-title":"Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials","volume":"11","author":"Uluer","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026032210420087200_aaoaf009-B122","author":"Vertex Pharmaceuticals","year":"2024"},{"key":"2026032210420087200_aaoaf009-B123","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jcf.2024.11.011","article-title":"Outcomes of prenatal use of elexacaftor\/tezacaftor\/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis","volume":"24","author":"Metcalf","year":"2025","journal-title":"J Cyst Fibrosis"},{"key":"2026032210420087200_aaoaf009-B124","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jcf.2025.03.009","article-title":"First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: report from the MODUL-CF study","volume":"24","author":"Bonnel","year":"2025","journal-title":"J Cyst Fibrosis"},{"key":"2026032210420087200_aaoaf009-B125","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jcf.2025.01.012","article-title":"Monitoring ETI effects over 1.7 years in an infant treated in utero, via breast milk and granules by repeated faecal elastase measurements","volume":"24","author":"Appelt","year":"2025","journal-title":"J Cyst Fibrosis"},{"key":"2026032210420087200_aaoaf009-B126","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026032210420087200_aaoaf009-B127","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","article-title":"Future therapies for cystic fibrosis","volume":"14","author":"Allen","year":"2023","journal-title":"Nat Commun"},{"key":"2026032210420087200_aaoaf009-B128","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S2213-2600(23)00324-7","article-title":"Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy","volume":"11","author":"Hisert","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/advance-article-pdf\/doi\/10.1513\/AnnalsATS.202408-800FR\/66545277\/annalsats.202408-800fr.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/23\/1\/17\/66545277\/annalsats.202408-800fr.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/23\/1\/17\/66545277\/annalsats.202408-800fr.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T14:42:08Z","timestamp":1774190528000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/23\/1\/17\/8438745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,17]]},"published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202408-800fr","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"2025-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}